{
    "nctId": "NCT01692210",
    "briefTitle": "The Effect of Dexmedetomidine of the Immune System",
    "officialTitle": "The Effect of Dexmedetomidine on Immunological Parameters of Women Undergoing Breast Cancer Surgery",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 20,
    "primaryOutcomeMeasure": "Pre and Post Surgical Lymphocyte Counts",
    "eligibilityCriteria": "Inclusion Criteria:\n\n3.1.1 - Women undergoing unilateral mastectomy for malignancy at MD Anderson Cancer Center.\n\n3.1.2 - Patients 18 years of age and older. There will be no upper age restriction.\n\n3.1.3 - Patients must sign a study-specific consent form.\n\nExclusion Criteria:\n\n3.2.1 - ASA 4\n\n3.2.2 - Contraindication to the use of dexmedetomidine.\n\n3.2.2.1. Decompensated congestive heart failure.\n\n3.2.2.2. Second and third degree heart block.\n\n3.2.2.2. Known allergy to dexmedetomidine or any of the medications used in the study\n\n3.2.3 - Patients taking clonidine for treatment of arterial hypertension.\n\n3.2.4 - Patients that are pregnant.\n\n3.2.5 - Patients taking opioids at the time of surgery.\n\n3.2.6 - Patients having plastic surgical reconstruction.\n\n3.2.7 - Recent chemotherapy (\\< 4 weeks).\n\n3.2.8 - Active autoimmune or immunological disease including but not limited to systemic lupus erythematous, rheumatoid arthritis and Sjogren's disease\n\n3.2.9 - Patient refusal to participate in the study.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}